Vikram Kansra

1.5k citations

52 papers · 1.2k indexed · h-index 19

Impact in

Oncology top 10%
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
Hepatology top 10%

Papers in

Anesthesiology and Pain Medicine 6
- Anesthesia and Sedative Agents 5
Oncology 21
- PARP inhibition in cancer therapy 11

Co-authors: Mustafa F. Lokhandwala Roberto D. Polakiewicz Michael J. Comb Lydia F. Dorner Tahir Hussain Sharon Lu Shefali Agarwal M F Lokhandwala
Journals: Journal of Clinical Oncology (7 papers)The Journal of Clinical Pharmacology (6 papers)Annals of Oncology (5 papers)Molecular Cancer Therapeutics (3 papers)Investigational New Drugs (2 papers)
Partner nations: United States United Kingdom Netherlands

In The Last Decade

Vikram Kansra

51 papers receiving 1.1k citations

Peers

Countries citing papers authored by Vikram Kansra

Since Specialization

Citations

This map shows the geographic impact of Vikram Kansra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vikram Kansra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vikram Kansra more than expected).

Fields of papers citing papers by Vikram Kansra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vikram Kansra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vikram Kansra. The network helps show where Vikram Kansra may publish in the future.

Co-authors

The 25 scholars most cited alongside Vikram Kansra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Vikram Kansra Line = papers co-authored together Vikram Kansra links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut Cell Host & Microbe ·Jason P. Lynch, Qin Lia, Analise Z. Reeves, Sena Bae, Dr. S. Shanmugavadivu, Lisa Houston, Jacqueline M. Tremblay, Florian I. Schmidt, Hidde L. Ploegh, Vikram Kansra, Jonathan N. Glickman, John M. Leong, Charles B. Shoemaker, Wendy S. Garrett, Cammie F. Lesser	2023	64
2	Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ACSS2, in patients with advanced solid tumors. Journal of Clinical Oncology ·Ruth Perets, Ano Kuhanathan, Meredith McKean, Andreas Goutopoulos, Omri Erez, Ankit Kumar Sharma, Hagop Youssoufian, Brian E. Schwartz, Vikram Kansra, Ali Fattaey	2022	6
3	Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects Investigational New Drugs ·Zhiyi Zhang, Jing Wang, Vikram Kansra, Xiaodong Wang	2018	3
4	Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects Supportive Care in Cancer ·Jing Wang, Zhiyi Zhang, Sharon Lu, Sixian Ding, Vikram Kansra, Xiaodong Wang	2018	14
5	The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial Annals of Oncology ·F S Guzmán Yunqué, Katherine E. Richardson, Mansoor Raza Mirza, Lucy Gilbert, Michel Fabbro, Anna V. Tinker, Rose Shayo, Andrés Redondo, J. S. Berek, Linn Woelber, Helen S. Pentikis, Kathleen N. Moore, Domenica Lorusso, Benedict B. Benigno, Sebastien Hazard, Philippe Follana, B.J. Rimel, Ursula A. Matulonis, Shefali Agarwal, Vikram Kansra	2017	8
6	Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer Investigational New Drugs ·Marie-Madeleine S. Barreto, Mirtes Moreira Silva, Sharon Lu, Vikram Kansra, Shefali Agarwal, Daivd J. Rehbein, Matthijs M. Tibben, Ling Chuan-rong, 泉田所, M. J. X. Hillebrand, Hilde Rosing, Jan H.M. Schellens, Jos H. Beijnen	2017	30
7	A phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovarian cancer (ENGOT-OV24/AVANOVA1) Annals of Oncology ·Mansoor Raza Mirza, F S Guzmán Yunqué, Morten Mau‐Sørensen, Michael J. Birrer, Rose Shayo, Martin Balslev Jørgensen, Katherine E. Richardson, Henrik Roed, Susanne Malander, Flemming Nielsen, Line Bjørge, Ulrik Lassen, 李涤臣, Kim Brøsen, Vikram Kansra, Johanna Mäenpää	2017	8
8	Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant Annals of Oncology ·Sally Barbour, Teresa Smit, Rose Shayo, Daniel Powers, Siddharth Arora, Vikram Kansra, Matti Aapro, Jørn Herrstedt	2017	7
9	Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients Cancer Chemotherapy and Pharmacology ·Marie-Madeleine S. Barreto, Hilde Rosing, Mirtes Moreira Silva, Daivd J. Rehbein, Vikram Kansra, Mitesh Sanghvi, Matthijs M. Tibben, Ling Chuan-rong, Jan H.M. Schellens, Jos H. Beijnen	2017	25
10	Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P‐glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers The Journal of Clinical Pharmacology ·Xiaodong Wang, Zhiyi Zhang, Sujata Arora, Daivd J. Rehbein, Jing Wang, Daniel Powers, Xun Pan, Sharon Lu, Vikram Kansra	2017	14
11	A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection PLoS ONE ·David Gardiner, Jay Lalezari, Eric Lawitz, Michael A. DiMicco, R. Ghalib, K. Rajender Reddy, Kyong‐Mi Chang, Mark Sulkowski, E. C. HILL, Jeffrey Anderson, Bing He, Vikram Kansra, Fiona McPhee, Megan Wind‐Rotolo, Dennis M. Grasela, M. J. Selby, Alan J. Korman, Israel Lowy	2013	197
12	Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening Molecular Cancer Therapeutics ·Richard J. Rickles, Winnie F. Tam, Thomas P. Giordano, Laura Pierce, Ahmel Arshad, Douglas W. McMillin, Takawan Sooksridang, David Crowe, Mei Chen, William Avery, Vikram Kansra, Steffan T. Nawrocki, Jennifer S. Carew, Francis J. Giles, Constantine S. Mitsiades, Alexis A. Borisy, Kenneth C. Anderson, Margaret Lee	2012	13
13	Development and validation of a liquid chromatography–tandem mass spectrometry assay for the simultaneous quantitation of prednisolone and dipyridamole in human plasma and its application in a pharmacokinetic study Journal of Pharmaceutical and Biomedical Analysis ·Mei Chen, Camille Granvil, Qin Ji, Zhiyi Zhang, Mahesh V. Padval, Vikram Kansra	2009	10
14	Biotransformation and in vitro assessment of metabolism-associated drug–drug interaction for CRx-102, a novel combination drug candidate Journal of Pharmaceutical and Biomedical Analysis ·Zhiyi Zhang, Y Biard, Jennifer Chen, Mahesh V. Padval, Vikram Kansra	2009	11
15	Small molecule antagonists of the CC chemokine receptor 4 (CCR4) Bioorganic & Medicinal Chemistry Letters ·Laura Alejandra Pelegrín, Ramesh Singh, Jerome Green, С. С. Скворцова, Zhan Shi, Shaowu Chen, Jingjing Liu, R.T. Hows, Kenneth G. Carson, Wei Yin, Vikram Kansra, José-Ángel Gonzalo, Anthony J. Coyle, Bruce Jaffee, Timothy D. Ocain, Birgitte Ravn, Gregory J. LaRosa, Geraldine Harriman	2007	22
16	Hyperphosphorylation of Na-Pump Contributes to Defective Renal Dopamine Response in Old Rats Journal of the American Society of Nephrology ·Mohammad Asghar, Vikram Kansra, Tahir Hussain, Mustafa F. Lokhandwala	2001	23
17	Phosphatidylinositol 3-Kinase-dependent Extracellular Calcium Influx Is Essential for CX3CR1-mediated Activation of the Mitogen-activated Protein Kinase Cascade Journal of Biological Chemistry ·Vikram Kansra, Christopher J. Groves, José Carlos Gutierrez‐Ramos, Roberto D. Polakiewicz	2001	49
18	Renal Dopamine Receptor Signaling Mechanisms in Spontaneously Hypertensive and Fischer 344 Old Rats Clinical and Experimental Hypertension ·Tahir Hussain, Vikram Kansra, Mustafa F. Lokhandwala	1999	16
19	A Mitogen-activated Protein Kinase Pathway Is Required for μ-Opioid Receptor Desensitization Journal of Biological Chemistry ·Roberto D. Polakiewicz, P Manque, Lydia F. Dorner, Vikram Kansra, Michael J. Comb	1998	120
20	Dopamine Fails to Stimulate Protein Kinase C Activity in Renal Proximal Tubules of Spontaneously Hypertensive Rats Clinical and Experimental Hypertension ·Vikram Kansra, E. E. Serebryannikov, M F Lokhandwala	1995	18

About Vikram Kansra

Vikram Kansra is a scholar working on Anesthesiology and Pain Medicine, Oncology, Reproductive Medicine, Hepatology and Statistics and Probability, having authored 52 papers that have together received 1.2k indexed citations. Recurring topics across this work include Nausea and vomiting management (14 papers), Anesthesia and Pain Management (11 papers), PARP inhibition in cancer therapy (11 papers), Ion Transport and Channel Regulation (8 papers), Anesthesia and Sedative Agents (5 papers), Ovarian cancer diagnosis and treatment (4 papers), Pathogenesis and Treatment of Hiccups (4 papers) and Statistical Methods in Clinical Trials (3 papers). The work is most often cited by research in Oncology (346 citations), Hepatology (82 citations), Immunology (197 citations), Cellular and Molecular Neuroscience (133 citations) and Physiology (184 citations). Vikram Kansra has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Mustafa F. Lokhandwala, Roberto D. Polakiewicz, Michael J. Comb, Lydia F. Dorner, Tahir Hussain, Sharon Lu, Shefali Agarwal, M F Lokhandwala, Sujata Arora and Allen Poma. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Clinical Pharmacology, Annals of Oncology, Molecular Cancer Therapeutics and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact